Palantir Q2 FY12/24 Earnings Review

DISCLAIMER: This note is intended for US recipients only and, in particular, is not directed at, nor intended to be relied upon by any UK recipients. Any information or analysis in this note is not an offer to sell or the solicitation of an offer to buy any securities. Nothing in this note is intended to be investment advice and nor should it be relied upon to make investment decisions. Cestrian Capital Research, Inc., its employees, agents or affiliates, including the author of this note, or related persons, may have a position in any stocks, security, or financial instrument referenced in this note. Any opinions, analyses, or probabilities expressed in this note are those of the author as of the note's date of publication and are subject to change without notice. Companies referenced in this note or their employees or affiliates may be customers of Cestrian Capital Research, Inc. Cestrian Capital Research, Inc. values both its independence and transparency and does not believe that this presents a material potential conflict of interest or impacts the content of its research or publications.

“The Salesforce Of Killing People”

by Alex King, CEO, Cestrian Capital Research, Inc

I love the Internet. I have always loved the Internet, but the more it seeps into society the more I love it. Yes, yes, you have the brain rot caused by social media and so forth, you have the most perfect disinformation machine ever invented, and you have all the elements needed for the machine to become sentient and demote the wetware to the most basic of tasks like taking out the trash. But on the plus side you also get to see the kind of commentary in securities research that you just don’t get on Wall Street. Or at least, not published by Wall Street!

Palantir ($PLTR) just printed their Q2 in the middle of a fairly rough probably-correction-probably-not-Armageddon period in the market - and the stock held up nicely, which is unusual at present. That alone is a bullish sign I would say.

Here’s the headlines:

Below - available to paying subscribers of all tiers here - we review the fundamentals, the valuation, the stock chart, our rating and price target. Read on folks.